Press View database covers global pharmaceutical and biotech companies daily announcements on drug development and corporate updates.
Database covers more than 4,500 active companies that includes development and commercial drugs companies.
Customized support for the below data fields,
Provides comprehensive analysis on drug research and market innovations with key data attributes.
Drug research expenses and success rates depends on molecule type and indication,
Trend analysis covers detailed information on Companies, Drugs, Patents and Sales. Topics covered in the database are,
SAN DIEGO, Aug. 06, 2019/-- Oncternal Therapeutics, Inc.,a clinical-stage biotechnology company developing potential first-in-class product candidates for cancers with critical unmet medical need, today announced that it has opened for enrollment its randomized Phase 2 study of cirmtuzumab, a ROR1-targeted monoclonal antibody, combined with ibrutinib in patients with chronic lymphocytic leukemia (CLL).Read more..
CAMBRIDGE, Mass., Aug. 06, 2019/-- Evelo Biosciences, Inc, a biotechnology company developing oral biologics that act on cells in the small intestine with systemic therapeutic effects, today announced positive interim clinical data from the first cohort of patients with mild to moderate psoriasis from its ongoing Phase 1b trial of EDP1815, its clinical candidate for the treatment of inflammatory diseases.Read more..
Basel, 06 August 2019 - Basilea Pharmaceutica Ltd,today announced positive top-line results for the Phase 3 TARGET trial in ceftobiprole for the treatment of patients with acute bacterial skin and soft tissue infections (ABSSSI) was investigated.Read more..
Paris and Tarrytown, New York - August 6, 2019 - A pivotal phase III trial evaluating Dupixent® (dupilumab) in the treatment of severe atopic dermatitis in children aged 6 to 11 years met its endpoints main and secondary. Dupixent is the first and only biologic drug to have positive results in this category of pediatric patients with atopic dermatitis.Read more..